Document:

ex_325097.htm

Exhibit 10.10

 

EXECUTION

 

 

 

 

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

 

 

 

 

 

EXECUTION

 

TABLE OF CONTENTS

 

	1.	
			Definitions

				1
	 	 	 	 
	
			2.

				
			Registration Rights

				5
	 	 	 	 
	 	
			2.1

				
			Demand Registration

				5
	 	 	 	 
	 	
			2.2

				
			Company Registration

				6
	 	 	 	 
	 	
			2.3

				
			Underwriting Requirements

				7
	 	 	 	 
	 	
			2.4

				
			Obligations of the Company

				8
	 	 	 	 
	 	
			2.5

				
			Furnish Information

				9
	 	 	 	 
	 	
			2.6

				
			Expenses of Registration

				10
	 	 	 	 
	 	
			2.7

				
			Delay of Registration

				10
	 	 	 	 
	 	
			2.8

				
			Indemnification

				10
	 	 	 	 
	 	
			2.9

				
			Reports Under Exchange Act

				12
	 	 	 	 
	 	
			2.10

				
			Limitations on Subsequent Registration Rights

				13
	 	 	 	 
	 	
			2.11

				
			“Market Stand-off” Agreement

				13
	 	 	 	 
	 	
			2.12

				
			Restrictions on Transfer

				13
	 	 	 	 
	 	
			2.13

				
			Termination of Registration Rights

				15
	 	 	 	 
	
			3.

				
			Information Rights

				15
	 	 	 	 
	 	
			3.1

				
			Delivery of Financial Statements

				15
	 	 	 	 
	 	
			3.2

				
			Inspection

				16
	 	 	 	 
	 	
			3.3

				
			INTENTIONALLY OMITTED

				16
	 	 	 	 
	 	
			3.4

				
			Termination of Information Rights

				16
	 	 	 	 
	 	
			3.5

				
			Confidentiality

				16
	 	 	 	 
	
			4.

				
			Rights to Future Stock Issuances

				17
	 	 	 	 
	 	
			4.1

				
			Right of First Offer

				17
	 	 	 	 
	 	
			4.2

				
			Termination

				18
	 	 	 
	
			5.

				
			Additional Covenants

				18
	 	 	 	 
	 	
			5.1

				
			Insurance

				18
	 	 	 	 
	 	
			5.2

				
			Employee Agreements

				18
	 	 	 	 
	 	
			5.3

				
			Employee Stock

				19
	 	 	 	 
	 	
			5.4

				
			INTENTIONALLY OMITTED

				19
	 	 	 	 
	 	
			5.5

				
			Milestone Payments

				19
	 	 	 	 
	 	
			5.6

				
			Board Matters

				20

 

i

 

 

	 	
			5.7

				
			Successor Indemnification

				20
	 	 	 	 
	 	
			5.8

				
			Termination of Covenants

				20
	 	 	 	 
	 	
			5.9

				
			Indemnification Matters

				20
	 	 	 	 
	
			6.

				
			Miscellaneous

				21
	 	 	 	 
	 	
			6.1

				
			Successors and Assigns

				21
	 	 	 	 
	 	
			6.2

				
			Governing Law

				21
	 	 	 	 
	 	
			6.3

				
			Counterparts

				21
	 	 	 	 
	 	
			6.4

				
			Titles and Subtitles

				22
	 	 	 	 
	 	
			6.5

				
			Notices

				22
	 	 	 	 
	 	
			6.6

				
			Amendments and Waivers

				22
	 	 	 	 
	 	
			6.7

				
			Severability

				23
	 	 	 	 
	 	
			6.8

				
			Aggregation of Stock

				23
	 	 	 	 
	 	
			6.9

				
			Additional Investors

				23
	 	 	 	 
	 	
			6.10

				
			Entire Agreement

				23
	 	 	 	 
	 	
			6.11

				
			Dispute Resolution

				23
	 	 	 	 
	 	
			6.12

				
			Waiver of Jury Trial

				24
	 	 	 	 
	 	
			6.13

				
			Expenses

				24
	 	 	 	 
	 	
			6.14

				
			Delays or Omissions

				24
	 	 	 	 
	 	
			6.15

				
			Specific Performance

				24

 

ii

 

 

EXECUTION

 

 

AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT

 

This Amended and Restated Investor Rights Agreement (this “Agreement”), dated as of this 13th day of November, 2020, by and among Eleison Pharmaceuticals Inc., a Delaware corporation (the “Company”), BDI Co., Ltd., a joint stock company organized under the laws of the Republic of Korea (“BDI”), and those certain stockholders of the Company listed on Schedule A hereto. For purposes of this Agreement, “Investor” shall mean BDI, the Stockholders listed on Schedule A and any Investor that becomes a party to this Agreement in accordance with Section 6.9 hereof.

 

BACKGROUND:

 

A.         The Company and the Investors entered into that certain Investor Rights Agreement, dated as of November 12, 2020 (the “Prior Agreement”);

 

B.          Pursuant to Section 6.6 of the Prior Agreement, the Prior Agreement may be amended with the written consent of the Company, BDI and the holders of at 67% of the Registrable Securities currently outstanding; and

 

C.         The Company, BDI, and the Investors party hereto which constitute holders of at 67% of the Registrable Securities currently outstanding desire to amend and restate the Prior Agreement and further agree that this Agreement (i) shall supersede the Prior Agreement, (ii) shall govern the rights of the Investors to cause the Company to register shares of Common Stock held by the Investors, to receive certain information from the Company, and to participate in future equity offerings by the Company, and (iii) shall govern certain other matters as set forth in this Agreement.

 

NOW, THEREFORE, intending to be legally bound, the parties hereby agree as follows:

 

1.          Definitions. For purposes of this Agreement:

 

1.1      “Affiliate” means, with respect to any specified Person, any other Person who, directly or indirectly, controls, is controlled by, or is under common control with such Person, including without limitation any general partner, managing member, officer or director of such Person or any investment fund now or hereafter existing that is controlled by one or more general partners or managing members of, or shares the same management company with, such Person.

 

1.2      “Certificate” means the Company’s Certificate of Incorporation, as in effect as of the applicable time.

 

1.3      “Company Intellectual Property” means all patents, patent applications, registered and unregistered trademarks, trademark applications, registered and unregistered service marks, service mark applications, tradenames, copyrights, trade secrets, domain names, information and proprietary rights and processes, similar or other intellectual property rights, subject matter of any of the foregoing, tangible embodiments of any of the foregoing, licenses in, to and under any of the foregoing, and any and all such cases that are owned or used by the Company in the conduct of the Company’s business as now conducted and as presently proposed to be conducted.

 

1

 

 

 

1.4      “Conversion” means the conversion of the Company from Eleison Pharmaceuticals, LLC, a Delaware limited liability company to a Delaware corporation pursuant to that certain Plan of Conversion, dated as of November 12, 2020.

 

1.5      “Common Stock” means shares of the Company’s common stock, par value $0.01 per share.

 

1.6      “Damages” means any loss, damage, claim or liability (joint or several) to which a party hereto may become subject under the Securities Act, the Exchange Act, or other federal or state law, insofar as such loss, damage, claim or liability (or any action in respect thereof) arises out of or is based upon: (i) any untrue statement or alleged untrue statement of a material fact contained in any registration statement of the Company, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto; (ii) an omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading; or (iii) any violation or alleged violation by the indemnifying party (or any of its agents or Affiliates) of the Securities Act, the Exchange Act, any state securities law, or any rule or regulation promulgated under the Securities Act, the Exchange Act, or any state securities law.

 

1.7      “Derivative Securities” means any securities or rights convertible into, or exercisable or exchangeable for (in each case, directly or indirectly), Common Stock, including options and warrants.

 

1.8      “Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

 

1.9      “Excluded Registration” means (a) a registration relating to the sale of securities to employees of the Company or a subsidiary pursuant to a stock option, stock purchase, or similar plan; (b) a registration relating to an SEC Rule 145 transaction; (c) a registration on any form that does not include substantially the same information as would be required to be included in a registration statement covering the sale of the Registrable Securities; or (d) a registration in which the only Common Stock being registered is Common Stock issuable upon conversion of debt securities that are also being registered.

 

1.10     “Exempted Securities” means (a) shares of Common Stock issued as a dividend or distribution on the Common Stock; (b) shares of Common Stock or options issued to employees or directors of, or consultants or advisors to, the Company or any of its subsidiaries pursuant to a plan, agreement or arrangement approved by the Board of Directors (including the affirmative vote of at least one of the Investor Designees); (c) shares of Common Stock or options issued to banks, equipment lessors or other financial institutions, or to real property lessors, pursuant to a debt financing, equipment leasing or real property leasing transaction approved by the Board of Directors (including the affirmative vote of at least one of the Investor Designees); (d) shares of Common Stock or options issued to suppliers or third party service providers in connection with the provision of goods or services pursuant to transactions approved by the Board of Directors (including the affirmative vote of at least one of the Investor Designees); (e) shares of Common Stock or options issued pursuant to the acquisition of another entity by the Company by merger, purchase of substantially all of the assets or other reorganization or to a joint venture agreement, provided that such issuances are approved by the Board of Directors (including the affirmative vote of at least one of the Investor Designees); (f) shares of Common Stock or options issued in connection with sponsored research, collaboration, technology license, development, OEM, marketing or other similar agreements or strategic partnerships approved by the Board of Directors (including the affirmative vote of at least one of the Investor Designees); or (g) shares of Common Stock issued in the IPO.

 

2

 

 

1.11      “Form S-1” means such form under the Securities Act as in effect on the date hereof or any successor registration form under the Securities Act subsequently adopted by the SEC.

 

1.12      “Form S-3” means such form under the Securities Act as in effect on the date hereof or any registration form under the Securities Act subsequently adopted by the SEC that permits incorporation of substantial information by reference to other documents filed by the Company with the SEC.

 

1.13      “GAAP” means generally accepted accounting principles in the United States.

 

1.14      “Holder” means any holder of Registrable Securities who is a party to this Agreement.

 

1.15      “Immediate Family Member” means a child, stepchild, grandchild, parent, stepparent, grandparent, spouse, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including, adoptive relationships, of a natural person referred to herein.

 

1.16      “Initiating Holders” means, collectively, Holders who properly initiate a registration request under this Agreement.

 

1.17      “Investor Designees” has the meaning set forth in the Voting Agreement.

 

1.18      “IPO” means the Company’s first underwritten public offering of its

Common Stock under the Securities Act.

 

1.19      “Key Employee” means any executive-level employee (including, vice president-level positions) as well as any employee who, either alone or in concert with others, develops, invents, programs, or designs any Company Intellectual Property.

 

1.20       “Major Investor” means any Investor that, individually or together with such Investor’s Affiliates, holds at least 10,000 shares of Registrable Securities (as adjusted for any stock split, stock dividend, combination, or other recapitalization or reclassification effected after the date hereof).

 

3

 

 

1.21      “New Securities” means, collectively, equity securities of the Company, whether or not currently authorized, as well as rights, options, or warrants to purchase such equity securities, or securities of any type whatsoever that are, or may become, convertible or exchangeable into or exercisable for such equity securities.

 

1.22      “Person” means any individual, corporation, partnership, trust, limited liability company, association or other entity.

 

1.23      “Registrable Securities” means (a) the Common Stock; (b) any Common Stock issued or issuable (directly or indirectly) upon conversion and/or exercise of any other securities of the Company acquired by the Investors after the date hereof; and (c) any Common Stock issued as (or issuable upon the conversion or exercise of any warrant, right, or other security that is issued as) a dividend or other distribution with respect to, or in exchange for or in replacement of, the shares referenced in clauses (a) and (b) above; excluding in all cases, however, any Registrable Securities sold by a Person in a transaction in which the applicable rights under this Agreement are not assigned pursuant to Section 6.1, and excluding for purposes of Section 2 any shares for which registration rights have terminated pursuant to Section 2.13 of this Agreement.

 

1.24      “Registrable Securities then outstanding” means the number of shares determined by adding the number of shares of outstanding Common Stock that are Registrable Securities and the number of shares of Common Stock issuable (directly or indirectly) pursuant to then exercisable and/or convertible securities that are Registrable Securities.

 

1.25       “Requisite Holders” means the holders then holding at least 67% of the

Registrable Securities then outstanding.

 

1.26      “Restricted Securities” means the securities of the Company required to be notated with the legend set forth in Section 2.12(b) hereof.

 

1.27      “SEC” means the Securities and Exchange Commission.

 

1.28      “SEC Rule 144” means Rule 144 promulgated by the SEC under the

 

1.29      “SEC Rule 145” means Rule 145 promulgated by the SEC under the Securities Act.

 

1.29      “Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

 

1.30      “Selling Expenses” means all underwriting discounts, selling commissions, and stock transfer taxes applicable to the sale of Registrable Securities, and fees and disbursements of counsel for any Holder, except for the fees and disbursements of the Selling Holder Counsel borne and paid by the Company as provided in Section 2.6.

 

4

 

 

1.31      “Voting Agreement” means the agreement among the Company, the Investors, and certain other stockholders of the Company, dated as of the date hereof, in the form of Exhibit F attached to this Agreement.

 

2.          Registration Rights. The Company covenants and agrees as follows:

 

2.1       Demand Registration.

 

(a)     Form S-1 Demand. If at any time after the earlier of (i) the five year anniversary of this Agreement, (ii) the one year anniversary of the date on which the Company receives marketing approval from the U.S. Food and Drug Administration for any Company product, or (iii) 180 days after the effective date of the registration statement for the IPO, the Company receives a request from Holders of at least 80% of the Registrable Securities then outstanding, then the Company shall (i) within ten days after the date such request is given, give notice thereof (the “Demand Notice”) to all Holders other than the Initiating Holders; (ii) as soon as practicable, and in any event within 60 days after the date such request is given by the Initiating Holders, file a Form S-1 registration statement under the Securities Act covering all Registrable Securities that the Initiating Holders requested to be registered and any additional Registrable Securities requested to be included in such registration by any other Holders, as specified by notice given by each such Holder to the Company within 20 days of the date the Demand Notice is given, and in each case, subject to the limitations of Sections 2.1(c) and 2.3; and (iii) use its best efforts to cause such Registrable Securities to be registered within six months after the date such request is given.

 

(b)     Form S-3 Demand. If at any time when it is eligible to use a Form S-3 registration statement, the Company receives a request from Holders of at least 20% of the Registrable Securities then outstanding that the Company file a Form S-3 registration statement with respect to outstanding Registrable Securities of such Holders having an anticipated aggregate offering price, net of Selling Expenses, of at least $3 million, then the Company shall (i) within ten days after the date such request is given, give a Demand Notice to all Holders other than the Initiating Holders; and (ii) as soon as practicable, and in any event within 45 days after the date such request is given by the Initiating Holders, file a Form S-3 registration statement under the Securities Act covering all Registrable Securities requested to be included in such registration by any other Holders, as specified by notice given by each such Holder to the Company within 20 days of the date the Demand Notice is given, and in each case, subject to the limitations of Sections 2.1(c) and 2.3.

 

(c)     Notwithstanding the foregoing obligations, if the Company furnishes to Holders requesting a registration pursuant to this Section 2.1 a certificate signed by the Company’s chief executive officer stating that in the good faith judgment of the Company’s Board of Directors it would be materially detrimental to the Company and its stockholders for such registration statement to either become effective or remain effective for as long as such registration statement otherwise would be required to remain effective, because such action would (i) materially interfere with a significant acquisition, corporate reorganization, or other similar transaction involving the Company; (ii) require premature disclosure of material information that the Company has a bona fide business purpose for preserving as confidential; or (iii) render the Company unable to comply with requirements under the Securities Act or Exchange Act, then the Company shall have the right to defer taking action with respect to such filing, and any time periods with respect to filing or effectiveness thereof shall be tolled correspondingly, for a period of not more than 90 days after the request of the Initiating Holders is given; provided, however, that the Company may not invoke this right more than once in any 12 month period; and provided further that the Company shall not register any securities for its own account or that of any other stockholder during such 90 day period other than an Excluded Registration.

 

5

 

 

(d)      The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to Section 2.1(a) (i) during the period that is 60 days before the Company’s good faith estimate of the date of filing of, and ending on a date that is 180 days after the effective date of, a Company-initiated registration, provided that the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective; (ii) after the Company has effected two registrations pursuant to Section 2.1(a); or (iii) if the Initiating Holders propose to dispose of shares of Registrable Securities that may be immediately registered on Form S-3 pursuant to a request made pursuant to Section 2.1(b). The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to Section 2.1(b) (1) during the period that is 30 days before the Company’s good faith estimate of the date of filing of, and ending on a date that is 90 days after the effective date of, a Company-initiated registration, provided that the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective; or (2) if the Company has effected one registration pursuant to Section 2.1(b) within the twelve month period immediately preceding the date of such request. A registration shall not be counted as “effected” for purposes of this Section 2.1(d) until such time as the applicable registration statement has been declared effective by the SEC, unless the Initiating Holders withdraw their request for such registration, elect not to pay the registration expenses therefor, and forfeit their right to one demand registration statement pursuant to Section 2.6, in which case such withdrawn registration statement shall be counted as “effected” for purposes of this Section 2.1(d).

 

2.2        Company Registration. If the Company proposes to register (including, for this purpose, a registration effected by the Company for stockholders other than the Holders) any of its securities under the Securities Act in connection with the public offering of such securities solely for cash (other than in an Excluded Registration), the Company shall, at such time, promptly give each Holder notice of such registration. Upon the request of each Holder given within 20 days after such notice is given by the Company, the Company shall, subject to the provisions of Section 2.3, cause to be registered all of the Registrable Securities that each such Holder has requested to be included in such registration. The Company shall have the right to terminate or withdraw any registration initiated by it under this Section 2.2 before the effective date of such registration, whether or not any Holder has elected to include Registrable Securities in such registration. The expenses (other than Selling Expenses) of such withdrawn registration shall be borne by the Company in accordance with Section 2.6.

 

6

 

 

2.3        Underwriting Requirements.

 

(a)         If, pursuant to Section 2.1, the Initiating Holders intend to distribute the Registrable Securities covered by their request by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to Section 2.1, and the Company shall include such information in the Demand Notice. The underwriter(s) will be selected by the Company and shall be reasonably acceptable to a majority in interest of the Initiating Holders. In such event, the right of any Holder to include such Holder’s Registrable Securities in such registration shall be conditioned upon such Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute their securities through such underwriting shall (together with the Company as provided in Section 2.4(e)) enter into an underwriting agreement in customary form with the underwriter(s) selected for such underwriting. Notwithstanding any other provision of this Section 2.3, if the managing underwriter(s) advise(s) the Initiating Holders in writing that marketing factors require a limitation on the number of shares to be underwritten, then the Initiating Holders shall so advise all Holders of Registrable Securities that otherwise would be underwritten pursuant hereto, and the number of Registrable Securities that may be included in the underwriting shall be allocated among such Holders of Registrable Securities, including the Initiating Holders, in proportion (as nearly as practicable) to the number of Registrable Securities owned by each Holder and submitted for inclusion in such offering or in such other proportion as shall mutually be agreed to by all such selling Holders; provided, however, that the number of Registrable Securities held by the Holders to be included in such underwriting shall not be reduced unless all other securities are first entirely excluded from the underwriting.

 

(b)      In connection with any offering involving an underwriting of shares of the Company’s capital stock pursuant to Section 2.2, the Company shall not be required to include any of the Holders’ Registrable Securities in such underwriting unless the Holders accept the terms of the underwriting as agreed upon between the Company and its underwriters, and then only in such quantity as the underwriters in their sole discretion determine will not jeopardize the success of the offering by the Company. If the total number of securities, including Registrable Securities, requested by stockholders to be included in such offering exceeds the number of securities to be sold (other than by the Company) that the underwriters in their reasonable discretion determine is compatible with the success of the offering, then the Company shall be required to include in the offering only that number of such securities, including Registrable Securities, which the underwriters and the Company in their sole discretion determine will not jeopardize the success of the offering. If the underwriters determine that less than all of the Registrable Securities requested to be registered can be included in such offering, then the Registrable Securities that are included in such offering shall be allocated among the selling Holders in proportion (as nearly as practicable) to the number of Registrable Securities owned by each selling Holder or in such other proportions as shall mutually be agreed to by all such selling Holders. Notwithstanding the foregoing, in no event shall (i) the number of Registrable Securities included in the offering be reduced unless all other securities (other than securities to be sold by the Company) are first entirely excluded from the offering, or (ii) the number of Registrable Securities included in the offering be reduced below 30% of the total number of securities included in such offering, unless such offering is the IPO, in which case the selling Holders may be excluded further if the underwriters make the determination described above and no other stockholder’s securities are included in such offering. For purposes of the provision in this Section 2.3(b) concerning apportionment, for any selling Holder that is a partnership, limited liability company, or corporation, the partners, members, retired partners, retired members, stockholders, and Affiliates of such Holder, or the estates and Immediate Family Members of any such partners, retired partners, members, and retired members and any trusts for the benefit of any of the foregoing Persons, shall be deemed to be a single “selling Holder,” and any pro rata reduction with respect to such “selling Holder” shall be based upon the aggregate number of Registrable Securities owned by all Persons included in such “selling Holder,” as defined in this sentence.

 

7

 

 

(c)      For purposes of Section 2.1, a registration shall not be counted as “effected” if, as a result of an exercise of the underwriter’s cutback provisions in Section 2.3(a), fewer than 50% of the total number of Registrable Securities that Holders have requested to be included in such registration statement are actually included.

 

2.4        Obligations of the Company. Whenever required under this Section 2 to effect the registration of any Registrable Securities, the Company shall, as expeditiously as reasonably possible:

 

(a)      prepare and file with the SEC a registration statement with respect to such Registrable Securities and use its commercially reasonable efforts to cause such registration statement to become effective and, upon the request of the Holders of a majority of the Registrable Securities registered thereunder, keep such registration statement effective for a period of up to 120 days or, if earlier, until the distribution contemplated in the registration statement has been completed; provided, however, that (i) such 120 day period shall be extended for a period of time equal to the period the Holder refrains, at the request of an underwriter of Common Stock (or other securities) of the Company, from selling any securities included in such registration, and (ii) in the case of any registration of Registrable Securities on Form S-3 that are intended to be offered on a continuous or delayed basis, subject to compliance with applicable SEC rules, such 120 day period shall be extended for up to 90 days, if necessary, to keep the registration statement effective until all such Registrable Securities are sold;

 

(b)      prepare and file with the SEC such amendments and supplements to such registration statement, and the prospectus used in connection with such registration statement, as may be necessary to comply with the Securities Act in order to enable the disposition of all securities covered by such registration statement;

 

(c)      furnish to the selling Holders such numbers of copies of a prospectus, including a preliminary prospectus, as required by the Securities Act, and such other documents as the Holders may reasonably request in order to facilitate their disposition of their Registrable Securities;

 

(d)      use its commercially reasonable efforts to register and qualify the securities covered by such registration statement under such other securities or blue-sky laws of such jurisdictions as shall be reasonably requested by the selling Holders; provided that the Company shall not be required to qualify to do business or to file a general consent to service of process in any such states or jurisdictions, unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act;

 

8

 

 

(e)      in the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and customary form, with the underwriter(s) of such offering;

 

(f)      use its commercially reasonable efforts to cause all such Registrable Securities covered by such registration statement to be listed on a national securities exchange or trading system and each securities exchange and trading system (if any) on which similar securities issued by the Company are then listed;

 

(g)      provide a transfer agent and registrar for all Registrable Securities registered pursuant to this Agreement and provide a CUSIP number for all such Registrable Securities, in each case not later than the effective date of such registration;

 

(h)      promptly make available for inspection by the selling Holders, any managing underwriter(s) participating in any disposition pursuant to such registration statement, and any attorney or accountant or other agent retained by any such underwriter or selected by the selling Holders, all financial and other records, pertinent corporate documents, and properties of the Company, and cause the Company’s officers, directors, employees, and independent accountants to supply all information reasonably requested by any such seller, underwriter, attorney, accountant, or agent, in each case, as necessary or advisable to verify the accuracy of the information in such registration statement and to conduct appropriate due diligence in connection therewith;

 

(i)      notify each selling Holder, promptly after the Company receives notice thereof, of the time when such registration statement has been declared effective or a supplement to any prospectus forming a part of such registration statement has been filed; and

 

(j)      after such registration statement becomes effective, notify each selling Holder of any request by the SEC that the Company amend or supplement such registration statement or prospectus.

 

(k)      In addition, the Company shall ensure that, at all times after any registration statement covering a public offering of securities of the Company under the Securities Act shall have become effective, its insider trading policy shall provide that the Company’s directors may implement a trading program under Rule 10b5-1 of the Exchange Act.

 

2.5        Furnish Information. It shall be a condition precedent to the obligations of the Company to take any action pursuant to this Section 2 with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information regarding itself, the Registrable Securities held by it, and the intended method of disposition of such securities as is reasonably required to effect the registration of such Holder’s Registrable Securities.

 

9

 

 

2.6        Expenses of Registration. All expenses (other than Selling Expenses) incurred in connection with registrations, filings, or qualifications pursuant to Section 2, including all registration, filing, and qualification fees; printers’ and accounting fees; fees and disbursements of counsel for the Company; and the reasonable fees and disbursements, not to exceed $50,000, of one counsel for the selling Holders selected by a majority in interest of the

 

selling Holders (“Selling Holder Counsel”), shall be borne and paid by the Company; provided, however, that the Company shall not be required to pay for any expenses of any registration proceeding begun pursuant to Section 2.1 if the registration request is subsequently withdrawn at the request of the Holders of a majority of the Registrable Securities to be registered (in which case all selling Holders shall bear such expenses pro rata based upon the number of Registrable Securities that were to be included in the withdrawn registration), unless the Holders of a majority of the Registrable Securities agree to forfeit their right to one registration pursuant to Sections 2.1(a) or 2.1(b), as the case may be; provided further that if, at the time of such withdrawal, the Holders shall have learned of a material adverse change in the condition, business, or prospects of the Company from that known to the Holders at the time of their request and have withdrawn the request with reasonable promptness after learning of such information then the Holders shall not be required to pay any of such expenses and shall not forfeit their right to one registration pursuant to Sections 2.1(a) or 2.1(b). All Selling Expenses relating to Registrable Securities registered pursuant to this Section 2 shall be borne and paid by the Holders pro rata on the basis of the number of Registrable Securities registered on their behalf.

 

2.7        Delay of Registration. No Holder shall have any right to obtain or seek an injunction restraining or otherwise delaying any registration pursuant to this Agreement as the result of any controversy that might arise with respect to the interpretation or implementation of this Section 2.

 

2.8         Indemnification.      If any Registrable Securities are included in a registration statement under this Section 2:

 

(a)      To the extent permitted by law, the Company will indemnify and hold harmless each selling Holder, and the partners, members, officers, directors, and stockholders of each such Holder; legal counsel and accountants for each such Holder; any underwriter (as defined in the Securities Act) for each such Holder; and each Person, if any, who controls such Holder or underwriter within the meaning of the Securities Act or the Exchange Act, against any Damages, and the Company will pay to each such Holder, underwriter, controlling Person, or other aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred; provided, however, that the indemnity agreement contained in this Section 2.8(a) shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Company, which consent shall not be unreasonably withheld, nor shall the Company be liable for any Damages to the extent that they arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of any such Holder, underwriter, controlling Person, or other aforementioned Person expressly for use in connection with such registration.

 

10

 

 

(b)      To the extent permitted by law, each selling Holder, severally and not jointly, will indemnify and hold harmless the Company, and each of its directors, each of its officers who has signed the registration statement, each Person (if any), who controls the Company within the meaning of the Securities Act, legal counsel and accountants for the Company, any underwriter (as defined in the Securities Act), any other Holder selling securities in such registration statement, and any controlling Person of any such underwriter or other Holder, against any Damages, in each case only to the extent that such Damages arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of such selling Holder expressly for use in connection with such registration; and each such selling Holder will pay to the Company and each other aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred; provided, however, that the indemnity agreement contained in this Section 2.8(b) shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Holder, which consent shall not be unreasonably withheld; and provided further that in no event shall the aggregate amounts payable by any Holder by way of indemnity or contribution under Sections 2.8(b) and 2.8(d) exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of fraud or willful misconduct by such Holder.

 

(c)         Promptly after receipt by an indemnified party under this Section

2.8 of notice of the commencement of any action (including any governmental action) for which a party may be entitled to indemnification hereunder, such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this Section 2.8, give the indemnifying party notice of the commencement thereof. The indemnifying party shall have the right to participate in such action and, to the extent the indemnifying party so desires, participate jointly with any other indemnifying party to which notice has been given, and to assume the defense thereof with counsel mutually satisfactory to the parties; provided, however, that an indemnified party (together with all other indemnified parties that may be represented without conflict by one counsel) shall have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying party, if representation of such indemnified party by the counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and any other party represented by such counsel in such action. The failure to give timely notice to the indemnifying party as aforesaid shall not relieve the indemnifying party of liability under this Section 2.8 except to the extent that the indemnifying party is actually prejudiced thereby.

 

(d)      To provide for just and equitable contribution to joint liability under the Securities Act in any case in which either: (i) any party otherwise entitled to indemnification hereunder makes a claim for indemnification pursuant to this Section 2.8 but it is judicially determined (by the entry of a final judgment or decree by a court of competent jurisdiction and the expiration of time to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case, notwithstanding the fact that this Section 2.8 provides for indemnification in such case, or (ii) contribution under the Securities Act may be required on the part of any party hereto for which indemnification is provided under this Section

2.8, then, and in each such case, such parties will contribute to the aggregate losses, claims, damages, liabilities, or expenses to which they may be subject (after contribution from others) in such proportion as is appropriate to reflect the relative fault of each of the indemnifying party and the indemnified party in connection with the statements, omissions, or other actions that resulted in such loss, claim, damage, liability, or expense, as well as to reflect any other relevant equitable considerations. The relative fault of the indemnifying party and of the indemnified party shall be determined by reference to, among other things, whether the untrue or allegedly untrue statement of a material fact, or the omission or alleged omission of a material fact, relates to information supplied by the indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission; provided, however, that, in any such case (x) no Holder will be required to contribute any amount in excess of the public offering price of all such Registrable Securities offered and sold by such Holder pursuant to such registration statement, and (y) no Person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) will be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation; and provided further that in no event shall a Holder’s liability pursuant to this Section 2.8(d), when combined with the amounts paid or payable by such Holder pursuant to Section 2.8(b), exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of willful misconduct or fraud by such Holder.

 

11

 

 

(e)      Unless otherwise superseded by an underwriting agreement entered into in connection with the underwritten public offering, the obligations of the Company and Holders under this Section 2.8 shall survive the completion of any offering of Registrable Securities in a registration under this Section 2, and otherwise shall survive the termination of this Agreement.

 

2.9        Reports Under Exchange Act. With a view to making available to the Holders the benefits of SEC Rule 144 and any other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or pursuant to a registration on Form S-3, the Company shall:

 

(a)      make and keep available adequate current public information, as those terms are understood and defined in SEC Rule 144, at all times after the effective date of the registration statement filed by the Company for the IPO;

 

(b)      use commercially reasonable efforts to file with the SEC in a timely manner all reports and other documents required of the Company under the Securities Act and the Exchange Act (at any time after the Company has become subject to such reporting requirements); and

 

(c)      furnish to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i) to the extent accurate, a written statement by the Company that it has complied with the reporting requirements of SEC Rule 144 (at any time after 90 days after the effective date of the registration statement filed by the Company for the IPO), the Securities Act, and the Exchange Act (at any time after the Company has become subject to such reporting requirements), or that it qualifies as a registrant whose securities may be resold pursuant to Form S-3 (at any time after the Company so qualifies); (ii) a copy of the most recent annual or quarterly report of the Company and such other reports and documents so filed by the Company; and (iii) such other information as may be reasonably requested in availing any Holder of any rule or regulation of the SEC that permits the selling of any such securities without registration (at any time after the Company has become subject to the reporting requirements under the Exchange Act) or pursuant to Form S-3 (at any time after the Company so qualifies to use such form).

 

12

 

 

2.10        Limitations on Subsequent Registration Rights. From and after the date of this Agreement, the Company shall not, without the prior written consent of the Requisite Holders, enter into any agreement with any holder or prospective holder of any securities of the Company that would (i) allow such holder or prospective holder to include such securities in any registration unless, under the terms of such agreement, such holder or prospective holder may include such securities in any such registration only to the extent that the inclusion of such securities will not reduce the number of the Registrable Securities of the Holders that are included; or (ii) allow such holder or prospective holder to initiate a demand for registration of any securities held by such holder or prospective holder; provided that this limitation shall not apply to any additional Investor who becomes a party to this Agreement in accordance with Section 6.9.

 

2.11        “Market Stand-off” Agreement. Each Holder hereby agrees that it will not, without the prior written consent of the managing underwriter, during the period commencing on the date of the final prospectus relating to the registration by the Company for its own behalf of shares of its Common Stock or any other equity securities under the Securities Act on a registration statement on Form S-1 or Form S-3, and ending on the date specified by the Company and the managing underwriter (such period not to exceed 180 days, but subject to extension as may be requested by the Company or an underwriter to the extent necessary to accommodate regulatory restrictions on (1) the publication or other distribution of research reports, and (2) analyst recommendations and opinions, including, but not limited to, the restrictions contained in FINRA Rule 2711(f)(4) or NYSE Rule 472(f)(4), or any successor provisions or amendments thereto, but only if such regulatory restrictions are applicable to the Company), (i) lend; offer; pledge; sell; contract to sell; sell any option or contract to purchase; purchase any option or contract to sell; grant any option, right, or warrant to purchase; or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable (directly or indirectly) for Common Stock held immediately before the effective date of the registration statement for such offering, or (ii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of such securities, whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of Common Stock or other securities, in cash, or otherwise. The foregoing provisions of this Section 2.11 shall apply only to the IPO, shall not apply to the sale of any shares to an underwriter pursuant to an underwriting agreement, or the transfer of any shares to any trust for the direct or indirect benefit of the Holder or the immediate family of the Holder, provided that the trustee of the trust agrees to be bound in writing by the restrictions set forth herein, and provided further that any such transfer shall not involve a disposition for value, and shall be applicable to the Holders only if all officers, directors and all stockholders individually owning more than one percent of the Company’s outstanding Common Stock are subject to the same restrictions.

 

2.12        Restrictions on Transfer.

 

(a) The Registrable Securities shall not be sold, pledged, or otherwise transferred, and the Company shall not recognize and shall issue stop-transfer instructions to its transfer agent with respect to any such sale, pledge, or transfer, except upon the conditions specified in this Agreement, which conditions are intended to ensure compliance with the provisions of the Securities Act. A transferring Holder will cause any proposed purchaser, pledgee, or transferee of the Registrable Securities held by such Holder to agree to take and hold such securities subject to the provisions and upon the conditions specified in this Agreement.

 

13

 

 

(b) Each certificate, instrument, or book entry representing (i) the Registrable Securities, and (ii) any other securities issued in respect of the securities referenced in clauses (i), upon any stock split, stock dividend, recapitalization, merger, consolidation, or similar event, shall (unless otherwise permitted by the provisions of Section 2.12(c)) be notated with a legend substantially in the following form:

 

THE SECURITIES REPRESENTED HEREBY HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933. SUCH SHARES MAY NOT BE SOLD, PLEDGED, OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR A VALID EXEMPTION FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF SAID ACT.

 

THE SECURITIES REPRESENTED HEREBY MAY BE TRANSFERRED ONLY IN ACCORDANCE WITH THE TERMS OF AN AGREEMENT BETWEEN THE COMPANY AND THE STOCKHOLDER, A COPY OF WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY.

 

The Holders consent to the Company making a notation in its records and giving instructions to any transfer agent of the Restricted Securities in order to implement the restrictions on transfer set forth in this Section 2.12.

 

(c)      The holder of such Restricted Securities, by acceptance of ownership thereof, agrees to comply in all respects with the provisions of this Section 2. Before any proposed sale, pledge, or transfer of any Restricted Securities, unless there is in effect a registration statement under the Securities Act covering the proposed transaction, the Holder thereof shall give notice to the Company of such Holder’s intention to effect such sale, pledge, or transfer. Each such notice shall describe the manner and circumstances of the proposed sale, pledge, or transfer in sufficient detail and, if reasonably requested by the Company, shall be accompanied at such Holder’s expense by either (i) a written opinion of legal counsel who shall, and whose legal opinion shall, be reasonably satisfactory to the Company, addressed to the Company, to the effect that the proposed transaction may be effected without registration under the Securities Act; (ii) a “no action” letter from the SEC to the effect that the proposed sale, pledge, or transfer of such Restricted Securities without registration will not result in a recommendation by the staff of the SEC that action be taken with respect thereto; or (iii) any other evidence reasonably satisfactory to counsel to the Company to the effect that the proposed sale, pledge, or transfer of the Restricted Securities may be effected without registration under the Securities Act, whereupon the Holder of such Restricted Securities shall be entitled to sell, pledge, or transfer such Restricted Securities in accordance with the terms of the notice given by the Holder to the Company. The Company will not require such a legal opinion or “no action” letter (x) in any transaction in compliance with SEC Rule 144; or (y) in any transaction in which such Holder distributes Restricted Securities to an Affiliate of such Holder for no consideration; provided that each transferee agrees in writing to be subject to the terms of this Section 2.12. Each certificate, instrument, or book entry representing the Restricted Securities transferred as above provided shall be notated with, except if such transfer is made pursuant to SEC Rule 144, the appropriate restrictive legend set forth in Section 2.12(b), except that such certificate instrument, or book entry shall not be notated with such restrictive legend if, in the opinion of counsel for such Holder and the Company, such legend is not required in order to establish compliance with any provisions of the Securities Act.

 

14

 

 

2.13       Termination of Registration Rights. The right of any Holder to request registration or inclusion of Registrable Securities in any registration pursuant to Sections 2.1 or  2.2 shall terminate upon the earliest to occur of:

 

(a)      the closing of a Deemed Liquidation Event, as such term is defined in the Certificate;

 

(b)       as to any Holder, such time as all Registrable Securities held by such Holder (together with any Affiliates of such Holder with whom such Holder must aggregate its sales under SEC Rule 144) can be sold in any three month period without registration under SEC Rule 144 (and without the requirement for the Company to be in compliance with the current public information required under Section (c)(1) of SEC Rule 144); or

 

(c)         three years following the consummation of an IPO.

 

3.          Information Rights.

 

3.1         Delivery of Financial Statements. The Company shall deliver to each Major Investor:

 

(a)      as soon as practicable, but in any event within 120 days after the end of each fiscal year of the Company (i) a balance sheet as of the end of such year, (ii) statements of income and of cash flows for such year, and (iii) a statement of stockholders’ equity as of the end of such year, all such financial statements audited and certified by an independent public accountant selected by the Company; such financial statements shall include a comparison to the prior year’s amounts (provided such prior year’s amounts were similarly audited and certified);

 

(b)      as soon as practicable, but in any event within 45 days after the end of each of the first three quarters of each fiscal year of the Company, unaudited statements of income and cash flows for such fiscal quarter, and an unaudited balance sheet and a statement of stockholders’ equity as of the end of such fiscal quarter, all prepared in accordance with GAAP (except that such financial statements may (i) be subject to normal year-end audit adjustments; and (ii) not contain all notes thereto that may be required in accordance with GAAP); and

 

(c)      such other information relating to the financial condition, business, prospects or corporate affairs of the Company as any Major Investor may from time to time reasonably request; provided, however, that the Company shall not be obligated under this Section 3.1(e) (i) that the Company reasonably determines in good faith to be a trade secret or confidential information (unless covered by an enforceable confidentiality agreement, in a form reasonably acceptable to the Company; or (ii) the disclosure of which would adversely affect the attorney-client privilege between the Company and its counsel.

 

15

 

 

If, for any period, the Company has any subsidiary whose accounts are consolidated with those of the Company, then in respect of such period the financial statements delivered pursuant to the foregoing sections shall be the consolidated and consolidating financial statements of the Company and all such consolidated subsidiaries.

 

Notwithstanding anything else in this Section 3.1 to the contrary, the Company may cease providing the information set forth in this Section 3.1 during the period starting with the date 30 days before the Company’s good-faith estimate of the date of filing of a registration statement if it reasonably concludes it must do so to comply with the SEC rules applicable to such registration statement and related offering; provided that the Company’s covenants under this Section 3.1 shall be reinstated at such time as the Company is no longer actively employing its commercially reasonable efforts to cause such registration statement to become effective.

 

3.2      Inspection. The Company shall permit each Major Investor, at such Major Investor’s expense, to visit and inspect the Company’s properties; examine its books of account and records; and discuss the Company’s affairs, finances, and accounts with its officers, during normal business hours of the Company as may be reasonably requested by the Major Investor; provided, however, that the Company shall not be obligated pursuant to this Section 3.2 to provide access to any information that it reasonably and in good faith considers to be a trade secret or confidential information (unless covered by an enforceable confidentiality agreement, in form reasonably acceptable to the Company) or the disclosure of which would adversely affect the attorney-client privilege between the Company and its counsel.

 

3.3      INTENTIONALLY OMITTED.

 

3.4      Termination of Information Rights. The covenants set forth in Sections 3.1 and 3.2, shall terminate and be of no further force or effect (i) immediately before the consummation of the IPO, or (ii) when the Company first becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act, or (iii) upon a Deemed Liquidation Event, as such term is defined in the Certificate, whichever event occurs first.

 

3.5     Confidentiality. Each Investor agrees that such Investor will keep confidential and will not disclose, divulge, or use for any purpose (other than to monitor its investment in the Company) any confidential information obtained from the Company pursuant to the terms of this Agreement (including notice of the Company’s intention to file a registration statement), unless such confidential information (a) is known or becomes known to the public in general (other than as a result of a breach of this Section 3.5 by such Investor), (b) is or has been independently developed or conceived by the Investor without use of the Company’s confidential information, or (c) is or has been made known or disclosed to the Investor by a third party without a breach of any obligation of confidentiality such third party may have to the Company; provided, however, that an Investor may disclose confidential information (i) to its attorneys, accountants, consultants, and other professionals to the extent necessary to obtain their services in connection with monitoring its investment in the Company; (ii) to any prospective purchaser of any Registrable Securities from such Investor, if such prospective purchaser agrees to be bound by the provisions of this Section 3.5; (iii) to any existing or prospective Affiliate, partner, member, stockholder, or wholly owned subsidiary of such Investor in the ordinary course of business, provided that such Investor informs such Person that such information is confidential and directs such Person to maintain the confidentiality of such information; or (iv) as may otherwise be required by law, provided that the Investor promptly notifies the Company of such disclosure and takes reasonable steps to minimize the extent of any such required disclosure.

 

16

 

 

4.          Rights to Future Stock Issuances.

 

4.1         Right of First Offer. Subject to the terms and conditions of this Section 4.1 and applicable securities laws, if the Company proposes to offer or sell any New Securities, the Company shall first offer such New Securities to each Major Investor. A Major Investor shall be entitled to apportion the right of first offer hereby granted to it among (i) itself, (ii) its Affiliates and (iii) its beneficial interest holders, such as limited partners, members or any other Person having “beneficial ownership,” as such term is defined in Rule 13d-3 promulgated under the Exchange Act, of such Major Investor (provided that such Affiliates and beneficial interest holders are “accredited Investors” under SEC regulations).

 

(a) The Company shall give notice (the “Offer Notice”) to each Major Investor, stating (i) its bona fide intention to offer such New Securities, (ii) the number of such New Securities to be offered, and (iii) the price and terms, if any, upon which it proposes to offer such New Securities.

 

(b) By notification to the Company within 20 days after the Offer Notice is given, each Major Investor may elect to purchase or otherwise acquire, at the price and on the terms specified in the Offer Notice, up to that portion of such New Securities which equals the proportion that the Common Stock then held by such Major Investor (including all shares of Common Stock issued, or then issuable (directly or indirectly), upon conversion and/or exercise, as applicable, of the Common Stock and any other Derivative Securities then held by such Major Investor) bears to the total Common Stock of the Company then outstanding (assuming full conversion and/or exercise, as applicable, of any Derivative Securities). At the expiration of such 20-day period, the Company shall promptly notify each Major Investor that elects to purchase or acquire all the shares available to it (each, a “Fully Exercising Investor”) of any other Major Investor’s failure to do likewise. During the ten day period commencing after the Company has given such notice, each Fully Exercising Investor may, by giving notice to the Company, elect to purchase or acquire, in addition to the number of shares specified above, up to that portion of the New Securities for which Major Investors were entitled to subscribe but that were not subscribed for by the Major Investors which is equal to the proportion that the Common Stock issued and held, or issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of any Derivative Securities then held by such Fully Exercising Investor bears to the Common Stock issued and held, or issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of any Derivative Securities then held, by all Fully Exercising Investors who wish to purchase such unsubscribed shares. The closing of any sale pursuant to this Section 4.1(b) shall occur within the later of 90 days of the date that the Offer Notice is given and the date of initial sale of New Securities pursuant to Section 4.1(c).

 

17

 

 

(c)        If all New Securities referred to in the Offer Notice are not elected to be purchased or acquired as provided in Section 4.1(b), the Company may, during the 90 day period following the expiration of the periods provided in Section 4.1(b), offer and sell the remaining unsubscribed portion of such New Securities to any Person or Persons at a price not less than, and upon terms no more favorable to the offeree than, those specified in the Offer Notice. If the Company does not enter into an agreement for the sale of the New Securities within such period, or if such agreement is not consummated within 30 days of the execution thereof, the right provided hereunder shall be deemed to be revived and such New Securities shall not be offered unless first reoffered to the Major Investors in accordance with this Section 4.1.

 

(d)         The right of first offer in this Section 4.1 shall not be applicable to Exempted Securities.

 

4.2       Termination. The covenants set forth in Section 4.1 and Section 4.2 shall terminate and be of no further force or effect (i) immediately before the consummation of the IPO, (ii) when the Company first becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act, or (iii) upon a Deemed Liquidation Event, as such term is defined in the Certificate, whichever event occurs first.

 

5.          Additional Covenants.

 

5.1      Insurance. The Company shall obtain, within ninety (90) days of the date hereof, from financially sound and reputable insurers Directors and Officers liability insurance and term “key-person” insurance on Edwin Thomas, in an amount and on terms and conditions satisfactory to the Board of Directors (including the affirmative vote of at least one of the Investor Designees), and will use commercially reasonable efforts to cause such insurance policies to be maintained until such time as the Board of Directors determines that such insurance should be discontinued. The key-person policy shall name the Company as loss payee, and neither policy shall be cancelable by the Company without prior approval by the Board of Directors (including the affirmative vote of at least one of the Investor Designees).

 

5.2      Employee Agreements. The Company will cause (a) each Key Employee now or hereafter employed by it or by any subsidiary (or engaged by the Company or any subsidiary as a consultant/independent contractor) with access to confidential information and/or trade secrets to enter into a nondisclosure agreement, (b) each employee now or hereafter employed by it or by any subsidiary who, either alone or in concert with others, develops, invents, programs, or designs any Company Intellectual Property to enter into a nondisclosure and proprietary rights assignment agreement, and (c) each Key Employee hereafter employed to enter into a noncompetition and nonsolicitation agreement in a form approved by the Board of Directors (including the affirmative vote of at least one of the Investor Designees). In addition, the Company shall not amend, modify, terminate, waive, or otherwise alter, in whole or in part, any of the above-referenced agreements or any restricted stock agreement between the Company and any employee, without the consent of the Board of Directors (including the affirmative vote of at least one of the Investor Designees).

 

18

 

 

5.3      Employee Stock. Unless otherwise approved by the Board of Directors (including the affirmative vote of at least one of the Investor Designees), all employees and consultants of the Company who, after the date hereof, receive options to purchase, or receive awards of shares of the Company’s capital stock after the date hereof shall be required to execute restricted stock or option agreements, as applicable, providing for (a) vesting of shares over a four-year period, with the first 25% of such shares vesting following 12 months of continued employment or service, and the remaining shares vesting in equal monthly installments over the following 36 months, and (b) a market stand-off provision substantially similar to that in Section

2.11. In addition, unless otherwise approved by the Board of Directors (including the affirmative vote of at least one of the Investor Designees), the Company shall retain a “right of first refusal” on employee transfers until the Company’s IPO and shall have the right to repurchase unvested shares at cost upon termination of employment of a holder of restricted stock.

 

5.4        INTENTIONALLY OMITTED.

 

5.5       Milestone Payments

 

(a)     Within ninety days after the first achievement of the applicable milestone events set forth in the table below (each such milestone event, a “Milestone Event”), the Company shall pay the applicable milestone payment set forth opposite the Milestone Event by wire transfer of immediately available funds to the Stockholders listed on Schedule B in accordance with each such Stockholder’s percentage share of the milestone payments as listed on Schedule B:

 

 

	
			Milestone Event

				
			Milestone

			Payment

			
	
			a. First marketing approval by the FDA for the

			Company’s drug candidate Glufosfamide

				
			$2 million

			
	
			b. First marketing approval by the FDA for the

			Company’s drug candidate ILC

				
			$1 million

			
	
			c. First marketing approval by the FDA for the

			Company’s drug candidate DBD

				
			$1 million

			
	
			d. First year annual worldwide product sales of

			Glufosfamide exceed $100 million

				
			$15 million

			
	
			e. First year annual worldwide product sales of

			Glufosfamide exceed $250 million

				
			$20 million

			

 

(b)     All milestone payments not made by the Company when due under this Agreement shall bear interest at a per annum rate equal to two percent (2%) over the then- current prime rate quoted by Citibank in New York City, such interest to run from the date upon which payment of such sum became due until payment thereof in full together with such interest.

 

(c)     Any such overdue payment shall, when made, be accompanied by, and credited first to, all interest so accrued. The milestone payments are nonrefundable.

 

19

 

 

5.6         Board Matters. Unless otherwise determined by the Board of Directors, the Board of Directors shall meet at least one time per calendar quarter, with one such meeting being held in-person at the Company’s offices or another location acceptable to the Board and the remaining meetings being held telephonically. The Company shall reimburse the nonemployee directors for all reasonable out-of-pocket travel expenses incurred (consistent with the Company’s travel policy) in connection with attending meetings of the Board of Directors.

 

5.7       Successor Indemnification. If the Company or any of its successors or assignees consolidates with or merges into any other Person and is not the continuing or surviving corporation or entity of such consolidation or merger, then to the extent necessary, proper provision shall be made so that the successors and assignees of the Company assume the obligations of the Company with respect to indemnification of members of the Board of Directors as in effect immediately before such transaction, whether such obligations are contained in the Company’s Bylaws, its Certificate, or elsewhere, as the case may be.

 

5.8       Termination of Covenants. The covenants set forth in this Section 5, except for Section 5.5 and Section 5.7, shall terminate and be of no further force or effect (i) immediately before the consummation of the IPO or (ii) when the Company first becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act, or (iii) upon a Deemed Liquidation Event, as such term is defined in the Certificate, whichever event occurs first.

 

5.9        Indemnification Matters. The Company hereby acknowledges that one (1) or more of the directors nominated to serve on the Board of Directors by the Investors (each an “Investor Director”) may have certain rights to indemnification, advancement of expenses and/or insurance provided by one or more of the Investors and certain of their Affiliates (collectively, the “Investor Indemnitors”). The Company hereby agrees (a) that it is the indemnitor of first resort (i.e., its obligations to any such Investor Director are primary and any obligation of the Investor Indemnitors to advance expenses or to provide indemnification for the same expenses or liabilities incurred by such Investor Director are secondary), (b) that it shall be required to advance the full amount of expenses incurred by such Investor Director and shall be liable for the full amount of all expenses, judgments, penalties, fines and amounts paid in settlement by or on behalf of any such Investor Director to the extent legally permitted and as required by the Certificate or Bylaws of the Company (or any agreement between the Company and such Investor Director), without regard to any rights such Investor Director may have against the Investor Indemnitors, and, (c) that it irrevocably waives, relinquishes and releases the Investor Indemnitors from any and all claims against the Investor Indemnitors for contribution, subrogation or any other recovery of any kind in respect thereof. The Company further agrees that no advancement or payment by the Investor Indemnitors on behalf of any such Investor Director with respect to any claim for which such Investor Director has sought indemnification from the Company shall affect the foregoing and the Investor Indemnitors shall have a right of contribution and/or be subrogated to the extent of such advancement or payment to all of the rights of recovery of such Investor Director against the Company. The Investor Directors and the Investor Indemnitors are intended third-party beneficiaries of this Subsection 5.9 and shall have the right, power and authority to enforce the provisions of this Subsection 5.9 as though they were a party to this Agreement.

 

20

 

 

5.10         Tax Treatment. The Company and the other parties hereto agree that, for U.S. federal and applicable state and local income tax purposes, the Conversion is intended to be

 

treated as an exchange of property by the predecessor of the Company (a partnership for applicable tax purposes) for stock of the Company (a corporation for applicable tax purposes) qualifying for tax-free treatment under Section 351(a) of the Internal Revenue Code of 1986, as amended (the “Code”), followed by the tax-free liquidation of such predecessor partnership and distribution of such stock to its partners, and that consistent with such treatment the payments to be made by the Company to the Stockholders entitled to such payments provided for under Section 5.5 are intended to be treated, and shall be reported, when and if made, as payments of “boot” being made to the recipients by the Company pursuant to Section 351(b) of the Code (except to the extent treated as interest payments pursuant to Section 483 of the Code), and that the Company and the other parties hereto shall file all tax returns and take all tax positions consistent with such intended tax treatment, unless otherwise required as a result of a determination pursuant to Section 1313 of the Code.

 

6.          Miscellaneous.

 

6.1      Successors and Assigns. The rights under this Agreement may be assigned (but only with all related obligations) by a Holder to a transferee of Registrable Securities that (i) is an Affiliate of a Holder; (ii) is a Holder’s Immediate Family Member or trust for the benefit of an individual Holder or one or more of such Holder’s Immediate Family Members; or (iii) after such transfer, holds at least 10,000 shares of Registrable Securities (subject to appropriate adjustment for stock splits, stock dividends, combinations, and other recapitalizations); provided, however, that (x) the Company is, within a reasonable time after such transfer, furnished with written notice of the name and address of such transferee and the Registrable Securities with respect to which such rights are being transferred; and (y) such transferee agrees in a written instrument delivered to the Company to be bound by and subject to the terms and conditions of this Agreement, including the provisions of Section 2.11. For the purposes of determining the number of shares of Registrable Securities held by a transferee, the holdings of a transferee (1) that is an Affiliate or stockholder of a Holder; (2) who is a Holder’s Immediate Family Member; or (3) that is a trust for the benefit of an individual Holder or such Holder’s Immediate Family Member shall be aggregated together and with those of the transferring Holder; provided further that all transferees who would not qualify individually for assignment of rights shall have a single attorney-in-fact for the purpose of exercising any rights, receiving notices, or taking any action under this Agreement. The terms and conditions of this Agreement inure to the benefit of and are binding upon the respective successors and permitted assignees of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and permitted assignees any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided herein.

 

6.2      Governing Law. This Agreement shall be governed by the internal law of the State of Delaware, without giving effect to principles of conflicts of laws.

 

6.3      Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.

 

21

 

 

6.4        Titles and Subtitles. The titles and subtitles used in this Agreement are for convenience only and are not to be considered in construing or interpreting this Agreement.

 

6.5       Notices.

 

(a)     All notices and other communications given or made pursuant to this Agreement shall be in writing and shall be deemed effectively given upon the earlier of actual receipt or (i) personal delivery to the party to be notified; (ii) when sent, if sent by electronic mail or facsimile during the recipient’s normal business hours, and if not sent during normal business hours, then on the recipient’s next business day; (iii) five days after having been sent by registered or certified mail, return receipt requested, postage prepaid; or (iv) one business day after the business day of deposit with a nationally recognized overnight courier, freight prepaid, specifying next-day delivery, with written verification of receipt. All communications shall be sent to the respective parties at their addresses as set forth on the signature pages hereto, or to the principal office of the Company and to the attention of the Chief Executive Officer, in the case of the Company, or to such email address, facsimile number, or address as subsequently modified by written notice given in accordance with this Section 6.5. If notice is given to the Company, a copy (which shall not constitute notice) shall also be sent to Steven M. Cohen, Morgan, Lewis & Bockius LLP, 502 Carnegie Center, Princeton, New Jersey, 08540. If notice is given to BDI, a copy (which shall not constitute notice) shall also be sent to Frederick Dorey, Cooley LLP, 3175 Hanover Street, Palo Alto, CA 94304.

 

(b)     Each Investor consents to the delivery of any stockholder notice pursuant to the Delaware General Corporation Law (the “DGCL”), as amended or superseded from time to time, by electronic transmission pursuant to Section 232 of the DGCL (or any successor thereto) at the electronic mail address or the facsimile number as on the books of the Company. To the extent that any notice given by means of electronic transmission is returned or undeliverable for any reason, the foregoing consent shall be deemed to have been revoked until a new or corrected electronic mail address has been provided, and such attempted electronic notice shall be ineffective and deemed to not have been given. Each Investor agrees to promptly notify the Company of any change in such stockholder’s electronic mail address, and that failure to do so shall not affect the foregoing.

 

6.6        Amendments and Waivers. Any term of this Agreement may be amended and the observance of any term of this Agreement may be waived (either generally or in a particular instance, and either retroactively or prospectively) only with the written consent of the Company and the Requisite Holders; provided that the Company may in its sole discretion waive compliance with Section 2.12(c) (and the Company’s failure to object promptly in writing after notification of a proposed assignment allegedly in violation of Section 2.12(c) shall be deemed to be a waiver); and provided further that any provision hereof may be waived by any waiving party on such party’s own behalf, without the consent of any other party. Notwithstanding the foregoing, (i) this Agreement may not be amended or terminated and the observance of any term hereof may not be waived with respect to any Investor without the written consent of such Investor, unless such amendment, termination, or waiver applies to all Investors in the same fashion (it being agreed that a waiver of the provisions of Section 4 with respect to a particular transaction shall be deemed to apply to all Investors in the same fashion if such waiver does so by its terms, notwithstanding the fact that certain Investors may nonetheless, by agreement with the Company, purchase securities in such transaction), and (ii) any provision hereof may be waived by the waiving party on such party’s own behalf. The Company shall give prompt notice of any amendment or termination hereof or waiver hereunder to any party hereto that did not consent in writing to such amendment, termination, or waiver. Any amendment, termination, or waiver effected in accordance with this Section 6.6 shall be binding on all parties hereto, regardless of whether any such party has consented thereto. No waivers of or exceptions to any term, condition, or provision of this Agreement, in any one or more instances, shall be deemed to be or construed as a further or continuing waiver of any such term, condition, or provision.

 

22

 

 

6.7      Severability. In case any one or more of the provisions contained in this Agreement is for any reason held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other provision of this Agreement, and such invalid, illegal, or unenforceable provision shall be reformed and construed so that it will be valid, legal, and enforceable to the maximum extent permitted by law.

 

6.8      Aggregation of Stock. All shares of Registrable Securities held or acquired by Affiliates shall be aggregated together for the purpose of determining the availability of any rights under this Agreement and such Affiliated persons may apportion such rights as among themselves in any manner they deem appropriate.

 

6.9      Additional Investors. Notwithstanding anything to the contrary contained herein, if the Company issues additional shares of Common Stock after the date hereof, whether pursuant to the Purchase Agreement or otherwise, any purchaser of such shares of Common Stock may become a party to this Agreement by executing and delivering an additional counterpart signature page to this Agreement, and thereafter shall be deemed an “Investor” for all purposes hereunder. No action or consent by the Investors shall be required for such joinder to this Agreement by such additional Investor, so long as such additional Investor has agreed in writing to be bound by all of the obligations as an “Investor” hereunder.

 

6.10     Entire Agreement. This Agreement (including any schedules hereto) constitutes the full and entire understanding and agreement among the parties with respect to the subject matter hereof, and any other written or oral agreement relating to the subject matter hereof existing between the parties is expressly canceled.

 

6.11     Dispute Resolution. The parties (a) hereby irrevocably and unconditionally submit to the jurisdiction of the state courts of Delaware and to the jurisdiction of the United States District Court for the District of Delaware for the purpose of any suit, action or other proceeding arising out of or based upon this Agreement, (b) agree not to commence any suit, action or other proceeding arising out of or based upon this Agreement except in the state courts of Delaware or the United States District Court for the District of Delaware, and (c) hereby waive, and agree not to assert, by way of motion, as a defense, or otherwise, in any such suit, action or proceeding, any claim that it is not subject personally to the jurisdiction of the above-named courts, that its property is exempt or immune from attachment or execution, that the suit, action or proceeding is brought in an inconvenient forum, that the venue of the suit, action or proceeding is improper or that this Agreement or the subject matter hereof may not be enforced in or by such court.

 

23

 

 

6.12     WAIVER OF JURY TRIAL. EACH PARTY HEREBY WAIVES ITS RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS AGREEMENT, THE OTHER TRANSACTION DOCUMENTS, THE SECURITIES OR THE SUBJECT MATTER HEREOF OR THEREOF. THE SCOPE OF THIS WAIVER IS INTENDED TO BE ALL-ENCOMPASSING OF ANY AND ALL DISPUTES THAT MAY BE FILED IN ANY COURT AND THAT RELATE TO THE SUBJECT MATTER OF THIS TRANSACTION, INCLUDING, WITHOUT LIMITATION, CONTRACT CLAIMS, TORT CLAIMS (INCLUDING NEGLIGENCE), BREACH OF DUTY CLAIMS, AND ALL OTHER COMMON LAW AND STATUTORY CLAIMS. THIS SECTION HAS BEEN FULLY DISCUSSED BY EACH OF THE PARTIES HERETO AND THESE PROVISIONS WILL NOT BE SUBJECT TO ANY EXCEPTIONS. EACH PARTY HERETO HEREBY FURTHER WARRANTS AND REPRESENTS THAT SUCH PARTY HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL, AND THAT SUCH PARTY KNOWINGLY AND VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL.

 

6.13     Expenses. Each party will bear its own costs in respect of any disputes arising under this Agreement. The prevailing party shall be entitled to reasonable attorney’s fees, costs, and necessary disbursements in addition to any other relief to which such party may be entitled. Each of the parties to this Agreement consents to personal jurisdiction for any equitable action sought in the U.S. District Court for the District of Delaware or any court of the State of Delaware having subject matter jurisdiction.

 

6.14     Delays or Omissions. No delay or omission to exercise any right, power, or remedy accruing to any party under this Agreement, upon any breach or default of any other party under this Agreement, shall impair any such right, power, or remedy of such nonbreaching or nondefaulting party, nor shall it be construed to be a waiver of or acquiescence to any such breach or default, or to any similar breach or default thereafter occurring, nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore or thereafter occurring. All remedies, whether under this Agreement or by law or otherwise afforded to any party, shall be cumulative and not alternative.

 

6.15     Specific Performance. The parties hereto hereby declare that it is impossible to measure in money the damages which will accrue to a party hereto or to their heirs, personal representatives, or assigns by reason of a failure to perform any of the obligations under this Agreement and agree that the terms of this Agreement shall be specifically enforceable. If any party hereto or his heirs, personal representatives, or assigns institutes any action or proceeding to specifically enforce the provisions hereof, any person against whom such action or proceeding is brought hereby waives the claim or defense therein that such party or such personal representative has an adequate remedy at law, and such person shall not offer in any such action or proceeding the claim or defense that such remedy at law exists.

 

[SIGNATURE PAGE FOLLOWS]

 

24

 

 

 

IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	
			 

				
			ELEISON PHARMACEUTICALS INC.

				
			 

			
	 	 	 	 
	
			 

				
			 

				
			 

				
			 

			
	
			 

				
			By:

				
			/s/ Edwin Thomas

				
			 

			
	
			 

				
			Name:

				
			Edwin Thomas

				
			 

			
	
			 

				
			Title:

				
			Chief Executive Officer

				
			 

			
	 	Address:	100 Overlook Center, 2nd Floor	 
	 	 	Princeton, NJ 08540 USA	 

 

 

[SIGNATURE PAGE TO AMENDED AND RESTATED INVESTORS RIGHTS AGREEMENT]

 

 

 

 

IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	
			 

				
			BDI CO., LTD.

				
			 

			
	 	 	 	 
	
			 

				
			 

				
			 

				
			 

			
	
			 

				
			By:

				
			/s/ AHN SEUNG MAN

				
			 

			
	 	 	 	 
	
			 

				
			Name:

				
			AHN SEUNG MAN

				
			 

			
	 	 	 	 
	
			 

				
			Title:

				
			ACTING CEO

				
			 

			
	 	 	 	 
	 	Address:	212, Gasan digital 1-ro	 
	 	 	 	 
	 	Geumcheon-gu, Seoul 08502	 

 

 

[SIGNATURE PAGE TO AMENDED AND RESTATED INVESTORS RIGHTS AGREEMENT]

 

 

 

 

IN WITNESS WHEREOF, the parties have execu1:ed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	
			FOR INDIVIDUALS:

				 	FOR ENTITIES:	
			 

			
	 	 	 	 	 	 
	Signature:	
			 

				 	
			Name of Entity:

				Eleison Pharma Holdings Inc.	
			 

			
	 	 	 	 	 	 
	Name:	
			 

				 	
			By:

				
			/s/ Edwin Thomas

				
			 

			
	 	 	 	 	 	 
	 	
			 

				 	Name:	Edwin Thomas	
			 

			
	 	 	 	 	 	 
	 	 	 	Title:	President	 

         

 

[SIGNATURE PAGE TO AMENDED AND RESTATED INVESTORS RIGHTS AGREEMENT]

 

 

 

 

DocuSign Envelope 10:EBFC4DE5-A33E-4862-B068-BD28EB9AF4A6

 

IN WITNESS WHEREOF, the parties have executed this Amended and Restated InvestorRights Agreement as of the date first written above.      

 

	 	 	 	
			General Partner:

			
	 	 	 	Eleison Investors
	 	 	 	General, L.P.
	
			FOR INDIVIDUALS:

				 	
			
			FOR ENTITIES:

			

				
			 

			
	 	 	 	 	 	 
	
			
			Signature:

			

				
			 

				 	
			Name of Entity:

				
			
			Eleison Investors II LP

			

				
			By: Eleison General,

			
	 	 	 	 	 	LLC; General Partner
	
			
			Name:

			

				
			 

				 	
			By:

				
			/s/ Frank Seidman

				
			 

			
	 	 	 	 	 	 
	 	
			 

				 	
			
			Name:

			

				
			
			
			
			Frank Seidman

			

			

			

				
			 

			
	 	 	 	 	 	 
	 	 	 	
			
			Title:

			

				
			
			Manager

			

				 

 

      

 

[SIGNATURE PAGE TO AMENDED AND RESTATED INVESTORS RIGHTS AGREEMENT]

 

 

 

 

OocuSign Envelope 10:EBFC4DE5-A33E-4862-8068-BD28EB9AF4A6

 

IN WITNESS WHEREOF, the par1ies have executed this Amended and Restated Investor Rights Agreement as of the date first written above.          

 

	 	 	 	
			General Partner:

			
	 	 	 	
			Eleison Investors

			
	 	 	 	
			General, L.P.

			
	
			FOR INDIVIDUALS:

				 	
			
			
			FOR ENTITIES:

			

			

				
			 

			
	 	 	 	 	 	 
	
			
			
			Signature:

			

			

				
			 

				 	
			Name of Entity:

				
			
			
			Eleison Investors LP

			

			

				
			By: Eleison General,

			
	 	 	 	 	 	
			LLC; General Partner

			
	
			
			
			Name:

			

			

				
			 

				 	
			By:

				
			/s/ Frank Seidman

				
			 

			
	 	 	 	 	 	 
	 	
			 

				 	
			
			
			Name:

			

			

				
			
			
			
			
			Frank Seidman

			

			

			

			

				
			 

			
	 	 	 	 	 	 
	 	 	 	
			
			
			Title:

			

			

				
			
			
			Manager

			

			

				 

 

    

 

[SIGNATURE PAGE TO AMENDED AND RESTATED INVESTORS RIGHTS AGREEMENT]

 

 

 

 

IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

 

	
			FOR INDIVIDUALS:

				 	
			
			FOR ENTITIES:

			

				
			 

			
	 	 	 	 	 	 
	
			
			Signature:

			

				
			 

				 	
			Name of Entity:

				 	
			 

			
	 	 	 	 	 	 
	
			
			Name:

			

				
			 

				 	
			By:

				
			 

				
			 

			
	 	 	 	 	 	 
	 	
			 

				 	
			
			Name:

			

				 	
			 

			
	 	 	 	 	 	 
	 	 	 	
			
			Title:

			

				 	 

 

 

[SIGNATURE PAGE TO AMENDED AND RESTATED INVESTORS RIGHTS AGREEMENT]

 

 

 

 

SCHEDULE A

Investors

 

 

 

	
			Name

			
	
			Eleison Pharma Holdings, Inc.

			
	
			Eleison Investors, L.P.

			
	
			Eleison Investors II, L.P.

			
	
			Thomas, Edwin

			
	
			Circle 3, LLC

			
	
			Schaeffer, James

			
	
			Schaeffer, Anthony

			
	
			Schaeffer, Robert

			
	
			Adam Share and Beth Share (Joint Tenants)

			
	
			Schaeffer 2012 Family Trust

			
	
			Dean, Daniel

			
	
			Merit Pharma LLC

			
	
			2007 IDT of J. Bonovitz & S. Bonovitz for E. Bonovitz

			
	
			2011 Bonovitz Family Trust

			
	
			Jill R. Bonovitz 2017 Revocable Trust

			
	
			Sheldon M. Bonovitz 2017 Revocable Trust

			
	
			Brian D. Alprin Trust dated 1/8/14

			
	
			Block, Brian

			
	
			Blum, David

			
	
			Bonovitz, Christopher

			
	
			Bonovitz, Sheldon and Jill

			
	
			CK Investments

			
	
			Carrino, Anthony

			
	
			Clancy, Thomas

			
	
			Delaney, Matthew and Debra

			
	
			D'Annunzio, Holly

			
	
			Donald E. Battle Living Trust

			
	
			Donato, Fran & Kristina

			
	
			Duffine, Geoffrey

			
	
			Drucker, Susan

			
	
			Gelman, Jonathan

			
	
			George Tyler Shipman Trust

			
	
			Goldenberg, Michael

			
	
			Grand Palm Partners LP

			
	
			Hefner, Patricia

			
	
			Hogan, Thomas

			
	
			Joel Morganroth MD Trust DTD 1/5/96 FBO Jason Morganroth

			
	
			Joel Morganroth MD Trust DTD 1/5/96

			

 

 

 

 

	
			FBO Jennifer Morganroth

			
	
			Joel Morganroth MD Trust DTD 1/5/96 FBO Jessica Morganroth

			
	
			Joel Morganroth Revocable Trust u/a/d 6/10/10

			
	
			JRJ Partners

			
	
			JRN Partners

			
	
			June Wolfson Trust

			
	
			K & AM Investors II, LP

			
	
			Kagan, Robert & Sunshine, Paula

			
	
			Kahn, Andrew

			
	
			Kaliner, Paul & Sharon

			
	
			Kaplin, Ned

			
	
			Kaplin Investment Partnership LP

			
	
			Keen, Victor

			
	
			Keith A. Morgan 2004 Family Trust

			
	
			Kevin Morgan Trust (The 1/4/67 Trust FBO Kevin Morgan)

			
	
			KHMA LP

			
	
			Kirwin, Marion Gordon

			
	
			KSM Partners LLC

			
	
			KSMR&S Profit Sharing Plan

			
	
			Kurz-Lindsay Revocable Trust

			
	
			Lawrence S. Smith Profit Sharing Plan

			
	
			MacManus, Thomas

			
	
			Mealey, Michael & Judith

			
	
			Morgan, Keith

			
	
			Mueskch, Joseph Niles

			
	
			Mullarkey, Kevin & Lisa

			
	
			Nissman, Michael

			
	
			Phillips 2010 Investments, LP

			
	
			Plott, Eric

			
	
			Rappaport, Jacob

			
	
			Rappaport, Jesse

			
	
			Rene Elizabeth Shipman Trust

			
	
			Sanghrka, Nimish & Niti

			
	
			Seidman, Frank & Kathleen

			
	
			Shipman, Fred

			
	
			Silverstein, Laurence

			
	
			Smith, Laurence

			
	
			Stephen Wolfson Trust

			
	
			Surgent, John

			
	
			Tierney, Brian

			
	
			T.J.R. Associates LP

			
	
			Varsity Investment Group

			
	Wiggers, Lane & Melissa

 

 

 

 

SCHEDULE B

Milestone Payments

 

 

 

 

 

 

Schedule B to the lnvestor Rights Agreement

 

 

	 	 	Milestone Distribution	 
	 	 	Percentage	 
	 	 	%	 
	 	 	 	 	 
	
			Eleison Pharma Holdings Inc.

				 	 	3.0	%
	
			Eleison Investors LP I

				 	 	35.2	%
	Eleison Investors LP II	 	 	19.7	%
	Circle 3, LLC	 	 	5.3	%
	
			Edwin Thomas

				 	 	1.3	%
	Anthony Schaeffer	 	 	2.5	%
	James Schaeffer	 	 	2.5	%
	Schaaffer Family Trust	 	 	1.0	%
	Adam and Beth Share	 	 	0.2	%
	Daniel Dean	 	 	0.2	%
	 	 	 	70.9	%
	 	 	 	 	 
	
			20071DT of J.Bonovitz & S. Bonovitz for E. Bonovitz

				 	 	0.1	%
	
			2011 Bonovitz Family Trust

				 	 	0.2	%
	
			Jill R.Bonovilz 2017 Revocable Trust

				 	 	0.1	%
	Sheldon M.Bonovitz 2017 Revocable Trust	 	 	0.1	%
	Brian D. Alprin Trust dated 1/8/14	 	 	0.1	%
	
			Block, Brian

				 	 	0.2	%
	
			Blum, David

				 	 	0.0	%
	
			Bonovitz, Christopher

				 	 	0.1	%
	Bonovitz, Sheldon and Jil	 	 	1.0	%
	CK lnvestments	 	 	0.1	%
	
			Carrino, Anthony

				 	 	0.0	%
	
			Clancy, Thomas

				 	 	0.1	%
	
			Delaney, Matthew and Debra

				 	 	0.0	%
	
			D'Annunzio, Holly

				 	 	0.0	%
	
			Donald E. Battle Living Trust

				 	 	0.1	%
	Donato, Fran & Kristina	 	 	0.4	%
	Duffine, Geoffrey	 	 	0.0	%
	
			Drucker, Susan

				 	 	0.2	%
	
			Eleison Pharma Holdings

				 	 	0.2	%
	
			Gelman, Jonathan

				 	 	0.0	%
	
			George Tyler Shipman Trust

				 	 	0.0	%
	
			Goldenberg, Michael

				 	 	0.2	%
	Grand Palm Partners LP	 	 	0.3	%
	Hafner, Patricia	 	 	0.0	%
	
			Hogan, Thomas

				 	 	0.0	%
	
			Joel Morganroth MD Trust DTD 1/5/96 FBO Jason Morganroth

				 	 	0.2	%
	Joel Morganroth MD Trust DTD 1/5/96 FBO Jennifer Morganroth	 	 	0.2	%
	Joel Morganroth MD Trust DTD 1/5/96 FBO Jessica Morganroth	 	 	0.2	%
	
			Joel Morganroth Revocable Trust u/a/d 6/10/10

				 	 	0.7	%
	
			JRJ Partners

				 	 	0.3	%
	
			JRN Partners

				 	 	0.4	%
	
			June Wolfson Trust

				 	 	0.3	%
	
			K & AM Investors II, LP

				 	 	0.1	%
	
			Kagan, Robert & Sunshine, Paula

				 	 	0.1	%
	
			Kahn, Andrew

				 	 	0.4	%
	
			Kaliner, Paul & Sharon

				 	 	0.0	%
	
			Kaplin, Ned

				 	 	1.8	%
	
			Kaplin Investment Partnership LP

				 	 	0.4	%
	
			Keen, Victor

				 	 	0.7	%
	
			Keith A. Morgan 2004 Family Trust

				 	 	0.1	%
	
			Kevin Morgan Trust (The 1/4/67 Trust FBO Kevin Morgan)

				 	 	0.1	%
	KHMA LP	 	 	0.1	%
	
			Kirwin, Marion Gordon

				 	 	0.7	%
	
			KSM Partners LLC

				 	 	0.2	%
	
			KSMR&S Profit Sharing Plan

				 	 	0.2	%
	Kurz-Lindsay Revocable Trust	 	 	0.6	%
	Lawrance S. Smith Profit Sharing Plan	 	 	2.4	%
	MacManus,Thomas	 	 	0.1	%
	
			Mealey, Michael & Judith

				 	 	0.0	%
	Morgan, Keith	 	 	0.1	%
	Mueskch, Joseph Niles	 	 	0.1	%
	Mullarkey, Kevin & Lisa	 	 	0.2	%
	Nissman, Michael	 	 	0.6	%
	
			Phillips 2010 Investments, LP

				 	 	0.0	%
	Plott, Eric	 	 	0.1	%
	
			Rappaport, Jacob

				 	 	0.0	%
	
			Rappaport, Jesse

				 	 	0.0	%
	
			Rene Elizabeth Shipman Trust

				 	 	0.0	%
	Sanghrajka, Nimiah & Niti	 	 	0.2	%
	Schaaffer, Anthony	 	 	0.2	%
	
			Schaaffer, James

				 	 	0.2	%
	
			Circle 3, LLC (R. Schaeffer)

				 	 	1.8	%
	Seidman, Frank & Kathleen	 	 	7.0	%
	Shipman, Fred	 	 	0.0	%
	
			Silverstein, Laurence

				 	 	0.3	%
	
			Smith, Laurence

				 	 	0.0	%
	Stephen Wolfson Trust	 	 	1.4	%
	Surgent, John	 	 	0.2	%
	
			Thomas, Edwin

				 	 	0.9	%
	
			Tiemey, Brian

				 	 	0.0	%
	
			T.J.R. Associates LP

				 	 	1.4	%
	Varsity Investment Group	 	 	0.0	%
	Wiggers, Lane & Melissa	 	 	0.4	%
	 	 	 	29.1	%
	 	 	 	 	 
	 	 	 	100.0	%ex_325114.htm

 

 

Exhibit 10.12

 

BioBridges, LLC

 

MASTER CLIENT SERVICES AGREEMENT

 

THIS MASTER CLIENT SERVICES AGREEMENT (this "Agreement") is made this April 16, 2021 (the "Effective Date") between BioBridges, LLC, a limited liability company duly organized under the laws of the Commonwealth of Massachusetts with a principal office at 167 Worcester Street, Suite #211, Wellesley, Massachusetts 02481 ("BioBridges") and Eleison Pharmaceuticals, a Corporation duly organized under the laws of Delaware with a principal office at 100 Overlook Center, 2nd Floor, Princeton, NJ 08540 ("Client"). In consideration of the mutual covenants and promises herein contained, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties do hereby agree as follows:

 

1.         Professional Services. BioBridges is engaged in the business of providing its professionals ("Professionals") to perform services for clients including those relating to pharmaceutical clinical trials and development. BioBridges will provide its Professionals to perform services for Client according to the terms and conditions of this Agreement and in accordance with executed Service Orders in substantially the form attached hereto as Exhibit A (each, a "Service Order"), which is incorporated herein by reference. Should any terms and conditions set forth in the Service Order conflict with the terms and conditions contained in this Agreement, the terms and conditions set forth in the Service Order will be understood to govern the agreement between the parties only if specifically stated as superseding a specific provision in the Agreement.

 

2.          Service Orders. During the term of this Agreement, BioBridges and Client will execute a Service Order for each project for which Client requires BioBridges Professionals (a "Project"). Upon execution of the applicable Service Order, Client will accept BioBridges Professionals to perform services for Client for the duration of time stated in said Service Order (the "Services"), subject to the terms and conditions of this Agreement. The parties agree that the terms and conditions of this Agreement shall apply to each such Service Order executed by the parties. Each Service Order shall set forth: (a) a description of the Services to be performed; (b) the term of the Service Order, (c) the location and timing of performance; and (d) any other terms and conditions applicable to the Services in question. No Service Order will be binding upon BioBridges or Client unless executed by both parties.

 

3.          Compensation; Invoicing and Payment.

 

(a)        BioBridges shall provide certain Services for Client Projects on a time and materials basis as set forth in the applicable Service Order. Client agrees to pay BioBridges for Services at the rates stated in the applicable Service Order. BioBridges will submit weekly invoices to Client for Services actually rendered based on timesheets for each BioBridges Project. Invoices shall be sent by email to clinical@eleison-pharma.com . The invoice shall indicate the number of hours worked, and the dates when Services were rendered and the fees for the Services performed. An authorized employee of Client shall approve each BioBridges Professionals weekly timesheet, indicating Client's satisfaction and approval of the worked hours.

 

Page 1 of 8

 

 

(b)        Applicable taxes (except employment taxes and taxes related to the net income ofBioBridges) are the responsibility of Client and shall be added to the charges payable by Client. Each invoice is due for payment by Client within thirty (30) days of receipt. Failure to pay any invoice within five (5) days of when due shall be considered a material breach of this Agreement. Any amounts not paid within thirty (30) days after they are due may be subject to interest at the rate of 1Y:z percent per month from the date due until such amount is paid in full. Client shall pay BioBridges' reasonable attorney's fees in any action brought to recover amounts due hereunder.

 

4.          Expenses. Client shall reimburse BioBridges for all pre-authorized out-of-pocket business and travel expenses incurred by the Professional as set forth specifically in each Service Order. Such expenses shall be specified separately in the applicable invoice. An authorized employee of Client shall

approve each BioBridges Professional members' weekly expense reimbursement form, indicating Client's approval of the expenses.

 

5.         Professionals. BioBridges agrees to use its best efforts to identify and provide qualified, pre­ screened BioBridges Professionals for the positions specified by Client, provided however, Client shall be under no obligation to retain the services of any particular person or to use BioBridges on an exclusive basis. BioBridges agrees to provide curriculum vitae, professional references and credential verifications for any Professionals providing Services, as requested by Client.

 

6.          Client Responsibilities.

 

(a)         Client shall provide the assigned BioBridges Professionals with access to and use of the personnel, facilities, equipment, data and information to the extent reasonably necessary to perform the Services. Client shall remain responsible to safeguard its network and data from any loss or disclosure.

 

(b)       Client is responsible for managing the day-to-day work of the BioBridges Professionals providing the Services, and advising on rules governing conduct, schedules and activities. BioBridges may participate in periodic progress meetings at the request of Client. Client may request periodic written reports from the assigned BioBridges Professionals about the progress of the Services and any particular assignment.

 

7.         Compliance. BioBridges agrees to comply with all applicable federal, state and local regulations, and any special safety provisions or reasonable Client policies specified by Client as applicable to the Services. For the sake of clarity, it is the express intent of the parties that there be no Transfer of Obligations, as defmed in 21 CFR 312.52, to BioBridges by operation of this Agreement or in connection with any Service Order entered into hereunder.

 

8.         Debarment. BioBridges represents and warrants to Client that neither it nor, to the knowledge of BioBridges, any Professional who will perform Services for Client under this Agreement, has been debarred nor is under consideration to be debarred by the United States Food and Drug Administration from working in or providing services to any pharmaceutical or biotechnology company under the Generic Drug Enforcement Act of 1991.

 

9.        Agreements with Professionals. BioBridges will ensure that each of its Professionals, prior to commencing Services for Client, executes a confidentiality and assignment of inventions agreement containing substantially similar confidentiality and invention disclosure/ownership obligations to those contained in this Agreement. BioBridges agrees that all BioBridges Professionals will, except to the extent otherwise provided explicitly herein, be obligated to provide a full assignment of any and all of Professional's rights in the Deliverables (as defmed herein below), which shall effectively vest in Client pursuant to the terms herein.

 

Page 2 of 8

 

10.        Confidentiality and Non-Disclosure. BioBridges and Client acknowledge their respective obligations under the Mutual Confidentiality Agreement (the "Mutual NDA''), a copy of which each party has in its possession. Nothing in this Agreement shall in any way limit the obligations ofBioBridges and Client under the Mutual NDA. In the event of any conflict between this Agreement and the Mutual NDA with respect to the protection of confidential information, the terms and provisions of the Mutual NDA shall prevail.

 

11.        BioBridges' Proprietary Business Information. Client acknowledges that BioBridges considers its fees and other fmancial information concerning this Agreement to be proprietary. Client will hold such proprietary information in confidence, and shall not disclose any of such information to any third parties, except as may be required by law, government regulation, or in connection with investor or potential investor presentations or fmancial audits.

 

12.       Non-Solicitation. Client acknowledges that the relationships ofBioBridges with its Professionals are a material asset of BioBridges. During the term of this Agreement and for a period of twelve (12) months following the termination or expiration thereof, Client shall not directly or indirectly (or attempt to do any of these things) interfere with BioBridges' relationship with, solicit, hire, contract with, or engage for employment or consultancy, for itself or any of its affiliates, unless Client obtains the prior written consent of BioBridges, any prospective Professional or Professional who at any time within twelve (12) months prior to Client's last contact with the person (a) was performing services through or on behalf of BioBridges, (b) was introduced to Client by or through BioBridges (including but not limited to, through presentation of resumes or interviews scheduled or conducted), or (c) about whom Client learned Confidential Information as a result of Client's contacts with BioBridges. Client acknowledges and agrees that any breach or attempted breach of this Section 12 will result in material harm to BioBridges. BioBridges may grant its written consent under this section 12. In the event that BioBridges grants its written consent under this Section 12, Client will pay to BioBridges a fee mutually agreed upon by BioBridges and Client (typically equivalent to 12 months of the person's base salary), within 30 days of the date the Professional is hired or engaged. Client shall not be restricted from hiring anyone who responded to general employment advertising from Client, with the exception that Client may not hire a BioBridges Professional that (except with the written consent ofBioBridges as above) (a) has been introduced to Client by BioBridges, or (b) has been engaged with Client through BioBridges.

 

13.       Insurance. During the term of this Agreement, BioBridges shall maintain in full force and effect insurance covering BioBridges and all Professionals in amounts not less than $1,000,000 in general liability Insurance per occurrence, $1,000,000 in general liability insurance per accident, $1,000,000 per occurrence in professional liability insurance and worker's compensation Insurance as required by applicable state law. BioBridges shall provide Client with certificates evidencing such insurance upon request by Client.

 

14.        Work Permits. If necessary, BioBridges shall insure that each of its Professionals has completed all required documentation to permit him or her to perform work in the United States in accordance with applicable federal immigration and naturalization laws.

 

Page 3 of 8

 

15.       Indemnification. Each party (the "Indemnifying Party") shall indemnify, defend and hold the other party, its affiliates, and their officers, directors, agents, employees, and independent contractors and their successors and assigns (each, an "Indemnified Party") harmless from and against any and all liability, obligation, damages, loss, award, fme, fee, charge, cost or expense of any kind, character or description (including reasonable legal fees) arising out of a claim, demand, suit, action or proceeding (each, a "Claim") brought by a third party against an Indemnified Party based upon or related to: (i) bodily injury or property damage caused by the gross negligence or willful misconduct of the Indemnifying Party; or (ii) the Indemnifying Party's material breach of this Agreement, except to the extent a Claim is the result of the gross negligence or willful misconduct of the Indemnified Party. As a condition of this indemnification obligation, an Indemnified Party must promptly notify the Indemnifying Party of a covered claim, tender to the Indemnifying Party (and/or its insurer) full authority to defend or settle the claim and must reasonably cooperate with the defense.

 

16.       Liability. Both parties' liability for damages to the other party for any cause whatsoever, and regardless of the form of action, whether in contract or tort, including negligence, shall be limited to the amount paid to the other party for the Services and Deliverables hereunder that cause the damages, or that is the subject matter of, or is directly related to, the cause of action. IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER PARTY OR ANY TlllRD PARTY FOR LOSS OF DATA, LOST PROFITS, RELIANCE, INCIDENTAL, CONSEQUENTIAL OR SPECIAL DAMAGES, INCLUDING, BUT NOT LIMITED TO, DAMAGES ARISING FROM EITHER PARTIES' PREPARATION TO ACCEPT, ACCEPTANCE OR USE OF ANY OF THE SERVICES AND DELIVERABLES HEREUNDER, EVEN IF THE OTHER PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.

 

 

17.        Equitable Relief. Each party hereto agrees that because monetary damages will be inadequate in the event of its breach or threatened breach of its obligations of confidentiality and/or non-solicitation under Sections 10, 11or 12 of this Agreement, the other party hereto shall also be entitled to injunctive relief and/or specific performance with respect to any such breach. In addition, such breaching party shall be liable to such non-breaching party for all expenses (including reasonable attorney's fees) and damages incurred by such non-breaching party on account of such breaching party's breach.

 

18.       Ownership of Data and Technology. Any data or other materials furnished to BioBridges or its Professionals by Client in connection with this Agreement shall remain the sole property of Client. BioBridges agrees to assign and hereby assigns to Client all rights to information, data, documentation, reports, results, inventions and other products of the Services (the "Deliverables") other than BioBridges Confidential Information. Except as described in the preceding sentence, all work products resulting from the Services that are "Works Made for Hire" as defmed in the U.S. Copyright Act and other copyrightable works will be deemed, upon creation, to be assigned to Client. Client will be free to use Deliverables for any and all legal purposes.

 

19.        Term and Termination. This Agreement shall remain in effect for two years and thereafter shall be automatically renewed for successive periods of one year unless notice of termination is received within thirty (30) days of the expiration date of this Agreement, including any renewal period. Notwithstanding the foregoing, either party may terminate this Agreement upon thirty (30) days written notice of which notice shall reference this Section 19. However, this Agreement shall continue to remain in effect with respect to any Service Orders in effect at the time of such termination, until such Service Orders are themselves terminated or the performance of Services thereunder is completed. Client may immediately terminate the Services of any BioBridges Professional, upon five (15) days written notice, with or without cause. No termination of this Agreement or any Service Order shall affect the obligation of Client to pay all amounts due to BioBridges for Services rendered and costs and expenses incurred through the date of termination of Services, as well as any termination fees if required pursuant to a Service Order. Upon termination of this Agreement for any reason, neither party shall have any further liability or obligation to the other party except for the payment of Services rendered, and reimbursement of costs and expenses incurred by BioBridges through the date of termination, and, if applicable, termination fees as may be required pursuant to a Service Order, except that the provisions of Sections 3, 4, 10, ll, 12, 15, 16, 17 18, 19, 20, and the Mutual NDA shall survive any termination of this Agreement.

 

Page 4 of 8

 

20.        Relationship. BioBridges and Client acknowledge that nothing in this Agreement shall in any way be construed to constitute BioBridges or Client as the agent, employee or representative of the other, and neither Client nor BioBridges shall have the power to bind the other party in any capacity. It is expressly agreed that no Professional supplied by BioBridges shall be eligible to participate in any employee benefit plan or program of Client. BioBridges shall pay all required taxes on BioBridges' income from Client under this Agreement. As between BioBridges and Client, BioBridges shall be solely responsible for any and all salaries, fees, state and federal taxes, withholding, FICA, workers compensation or other payments due in respect of the compensation paid to BioBridges or by BioBridges to its Professionals.

 

21.        Notices. All notices must be written and sent to the address or facsimile number identified in this Agreement or in a subsequent notice. All notices must be given: (a) by personal delivery, with receipt acknowledged, (b) by U.S. mail, or (3) by prepaid recognized next business day delivery service. Notices will be effective upon receipt. Notices to Client must be marked "Attention: Edwin Thomas" and if via e-mail, addressed to edwin.thomas@eleison-pharma.com . Notices to BioBridges must be marked "Attention: Jeff Souza," and if via e-mail, addressed to jsouza@biobridges.com. Notices and invoices shall be deemed received (a) if by personal delivery, on the date delivered; (b) if by U.S. mail, on the third business day following the date of such mailing; (c) if by next day delivery, on the date of delivery as evidenced by written records from a recognized courier service; or (d) ifby e-mail, when the recipient, by an e-mail sent to the sender's e-mail address stated in this Section 21, acknowledges having received that e-mail, with an automatic "read receipt" not constituting acknowledgment of an e-mail for purposes of this Section 21.

 

22.        General Provisions.

 

(a)        Client warrants that Client is not subject to any agreement or obligation with any other party, which would or could in any way conflict with Client's obligation under this Agreement, and that by entering into this Agreement, Client does not violate the terms of any other agreement with any other party.

 

(b)         BioBridges may list Client as a client of BioBridges for information purposes, but may not use Client's name or logo on advertising and promotional media without the written consent of Client.

 

(c)         This Agreement and the Mutual NDA represent the entire agreement between BioBridges and Client and, other than the executed Service Orders, there are no other agreements, oral or written, relating to the subject matter of this Agreement. Any amendment to or modification of this Agreement, or any Service Order, must be in writing and signed by an authorized corporate officer of each of BioBridges and Client. Notwithstanding, an e-mail between an authorized representative of Client and the Senior Vice President of BioBridges mutually agreeing to extend the term of any Service Order upon its expiration shall be sufficient to extend such Service Order, with all other remaining provisions remaining unaltered and in effect.

 

Page 5 of 8

 

 

(d)        This Agreement shall be construed in accordance with the laws of the Commonwealth of Massachusetts. Without limitation, Client hereby consents and submits to the jurisdiction of the state and federal courts in Massachusetts.

 

(e)        This Agreement shall bind and inure to the benefit of the parties hereto and any successor by reorganization, merger, consolidation or liquidation and any assignee of all or substantially all of its business or assets, but otherwise neither party may assign this Agreement without the mutual consent of the parties.

 

(f)        If any one or more of the provisions contained in this Agreement shall, for any reason, be held to be invalid, illegal or unenforceable in any respect, it shall not affect any other provisions of this Agreement. If any provision in this Agreement shall be held to be excessively broad, it shall be construed by limiting it so as to be enforceable to the extent compatible with applicable law.

 

(g)         Waiver by either party hereto of a breach of any provision of this Agreement shall not operate or be construed as a waiver of any subsequent breach.

 

(h)       After the expiration or termination of this Agreement, all provisions which specifically provide for survival beyond expiration or termination, including but not limited to all provisions regarding confidentiality, protection of proprietary rights and trade secrets, and non-solicitation of consultants, employees or contractors, shall survive until the expiration of any time period specified elsewhere in this Agreement with respect to the provision in question.

 

(i)          This Agreement may be executed in two counterparts, each of which shall be deemed to be an original, and shall suffice as proof of this Agreement.

 

Page 6 of 8

 

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first above written.

 

 

 

Page 7 of 8

 

BioBridges, LLC

 

MASTER CLIENT SERVICES AGREEMENT

EXIDBIT "A" SERVICE ORDER

 

This Service Order is an attachment to the Master Client Services Agreement by and between NAME ("Client") and BioBridges, LLC ("BioBridges") dated DATE (the "Master Client Services Agreement").

 

Client agrees to accept this Service Order according to the terms and conditions set forth in the Master Client Services Agreement, and at the rates specified in this Service Order, including applicable state sales tax.

 

	Client Contact:	NAME	 
	 	 	 
	Start Date:	DATE	 
	End Date:	DATE	 
	Length of Assignment:	LENGTH	 
	 	 	 
	Project Scope:	SCOPE	 
	 	 	 
	Hourly Work Rate:	 	$
	Hourly Travel Rate (excluding commute):	 	$
	 	 	 
	Client Purchase Order#: 	 	 
	Expenses:	Client approved, as applicable

 

IN WITNESS WHEREOF, the parties have executed this Service Order as of the date(s) signed below.

 

	"BioBridges"	 	"Client"
	 	 	 	 
	
			BioBridges, LLC

				 	Print Name:	 
	
			IRS Employer Identification Number (EIN):

			41-2162080

				 	IRS Employer Identification Number (EIN)
	By:	 	 	By:	 
	                             (Signature)	 	 	(Signature)
	 	 	 	 
	Print Name:	Jeff Souza	 	Print Nane:	 
	Title	President	 	Title:	 
	Date:	 	 	Date:	 
	 	 	 	 

 

Page 8 of 8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00339-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00339-of-00352.parquet"}]]